The Science of Cinnamon: Ancient Recognition, Now Examined by Modern Science

Cinnamomum verum — Species Identity, Safety Profile, and the Evidence Base for Repeated-Use Applications

Nalin Siriwardhana, PhD, FACN,   Nutritional Scientist

Published by Ceylon Nutritionals · Science & Education Series · March 2025

Thirty years of research into cinnamon's phytochemistry have established a mechanistically coherent picture of its biological activity. The critical finding of the past decade is that not all cinnamon species are equivalent — in composition, in the quality of their evidence base, or in their safety profile for repeated use. Species identity, coumarin burden, extract composition, and traceability materially affect both the interpretation of the scientific literature and the suitability of any cinnamon ingredient for repeated-use applications. Among the commercial species, Cinnamomum verum — Ceylon cinnamon, grown in Sri Lanka — is the most consistently characterised and the most rigorously studied in species-authenticated clinical research, with the lowest documented coumarin burden and the strongest provenance framework. This article reviews that evidence in full.

What makes that scientific conclusion particularly compelling is that it was arrived at independently — across civilisations, across more than two thousand years, and long before any of the molecular mechanisms were understood. In the first century AD, Pliny the Elder recorded that 350 grams of cinnamon were worth nearly five kilograms of silver — roughly fifteen times its value by weight.[1] Encyclopaedia Britannica records it as once more valuable than gold, and later the most profitable single spice in the Dutch East India Company's trade.[1] Cinnamon is confirmed in Egyptian ritual and embalming contexts by approximately 2000 BCE,[1] prescribed in the Charaka Samhita (~600 BCE), documented by Greek physicians Dioscorides and Galen, and catalogued by Ibn Sina (Avicenna) in his Canon of Medicine. Sri Lankan records document cinnamon on the island as far back as 1400 BCE.[20] Arab merchants concealed Ceylon as its source for centuries — fabricating myths recorded by Herodotus — because its origin was too commercially valuable to reveal. For nearly five consecutive centuries, three colonial empires competed to control the island that grew it.[20] Historical records do not constitute proof of modern pharmacological efficacy. But the consistency of that independent recognition — across unrelated cultures, medical traditions, and economic systems — is precisely what gives the modern scientific investigation its context and its significance.

── PART ONE · THE SCIENCE OF CINNAMON ──

Cinnamon belongs to the genus Cinnamomum within the family Lauraceae — the same ancient lineage as avocado, bay laurel, and camphor. Of the more than 250 species within this genus, four have become commercially significant. All share the same raw material: the inner bark of evergreen trees, stripped, dried, and allowed to curl into the scrolls we recognise as cinnamon sticks. The botany is straightforward. The chemistry inside that bark is not.

The Mahavamsa — Sri Lanka's ancient Pali chronicle dating to the 5th century BCE — lists cinnamon among the island's most valued exports. The fact that cinnamon's value was consistently recognised across independent civilisations frames a scientific question rather than answering one: what is in this bark that warranted such consistent attention? Thirty years of phytochemical research is now providing that answer.[20] The question that modern chemistry has spent the past thirty years answering is the one those ancient records implicitly ask: what exactly is in this bark that made it so consistently valuable to so many independent cultures? When analytical chemists began systematically characterising cinnamon in the 20th century, they found not one active compound but an entire pharmacological ecosystem — molecules from different chemical classes, each with distinct biological targets, each interacting with the others in ways that appear to amplify individual effects. The ancient instinct to reach for cinnamon in illness turns out to have been, with remarkable consistency, chemically justified.

The Principal Bioactive Compounds of Cinnamomum verum

── PART TWO · CLINICAL EVIDENCE ──

Understanding cinnamon's evidence base requires distinguishing three layers of evidence — historical recognition, mechanistic science, and human clinical trials — because they carry very different weight and should not be conflated.

Historical recognition (documented across civilisations from approximately 2000 BCE onward) establishes that cinnamon had consistent high value in trade and medicine. It does not, by itself, constitute proof of modern pharmacological efficacy. Mechanistic and preclinical science (developed primarily from the 1990s onward) has characterised specific molecular interactions — NF-κB modulation, GLUT4 upregulation, PI3K/Akt activation, COX-2 inhibition — that provide biologically plausible explanations for observed effects. These are largely in vitro and animal data. Human clinical evidence (most actively developed in the 2010s and 2020s) is the most scientifically robust layer, and it is also the most complex: study heterogeneity, species ambiguity, and inconsistent outcome reporting have made interpretation difficult. Consistent with assessments from the U.S. National Center for Complementary and Integrative Health (NCCIH, part of the National Institutes of Health), the cinnamon literature is complicated by variability in species identification, plant part used, extract composition, and study design,[19] and current evidence does not yet support definitive clinical use for any specific health condition. The most rigorous recent development — species-authenticated controlled trials using standardised C. zeylanicum extract — addresses these limitations directly and represents the highest-quality data currently available. The domains below report evidence at the layer it actually belongs in. Accordingly, the most reliable conclusions in the cinnamon literature are those derived from studies that clearly define species identity, extract composition, and dosage.

1 · Metabolic Health & Blood Glucose Regulation

This is the most comprehensively researched area of cinnamon's bioactivity in clinical science. Diabetes mellitus now affects approximately 10% of the global population,[8] with a far larger number in insulin-resistant or pre-diabetic states. Four distinct molecular pathways have been described in the preclinical literature through which cinnamon may influence glycaemic regulation: inhibition of alpha-glucosidase and alpha-amylase (slowing starch digestion and blunting post-meal glucose absorption); upregulation of GLUT4 transporter expression in skeletal muscle cells; activation of the PI3K/Akt signalling cascade; and potentiation of insulin receptor tyrosine kinase activity.[3]

The most methodologically rigorous recent clinical data comes from a 2025 randomised, double-blind, placebo-controlled trial (Muthukuda et al., PLoS ONE).[4] The extract was confirmed as Cinnamomum zeylanicum by species authentication, standardised to ≥30% polyphenols (PAC-A type, 15,298 mg/100g), with coumarin measured at only 0.01%, administered at 1,000 mg/day. The key finding was a statistically significant reduction in fasting blood glucose, with the effect more pronounced in participants with type 2 diabetes. LDL cholesterol was numerically lower in the treatment arm, but this difference did not reach statistical significance — a nuance the peer-review literature appropriately emphasises. A 2025 systematic review (Beheshti et al., Naunyn-Schmiedeberg's Archives of Pharmacology) confirmed a consistent pattern of anti-diabetic, anti-dyslipidaemic, and anti-inflammatory activity across study designs — while noting that larger-scale human trials remain warranted.[9]

In practice: The best-controlled recent data on cinnamon and blood glucose uses authenticated C. zeylanicum extract, standardised to a minimum 30% PAC-A polyphenols, at 1,000 mg/day. The evidence supports a statistically significant effect on fasting blood glucose. LDL cholesterol reduction was not statistically significant in this trial. Human evidence is most developed in metabolic endpoints; broader clinical use remains limited by study heterogeneity and the ongoing need for larger trials.

2 · Cardiovascular Health

A 2024 systematic review (Mohammadabadi & Jain, Archives of Medical Sciences: Atherosclerotic Diseases)[11] examined the mechanistic and early clinical cardiovascular literature for cinnamon, identifying several plausible cardioprotective pathways: preclinical and early clinical evidence for lipid modulation, anti-thrombotic effects through platelet aggregation inhibition, and anti-atherosclerotic properties observed in animal models. A 2017 Phase I safety and pharmacodynamic trial of authenticated C. zeylanicum (Ranasinghe et al., BMC Complementary and Alternative Medicine)[12] recorded early signals across several cardiovascular parameters over three months; the authors were appropriately cautious about the preliminary nature of those findings. The 2024 review explicitly states that larger, more rigorous clinical trials are needed before cardiovascular protection can be claimed with confidence. The current evidence establishes biological plausibility — coherent, mechanistically grounded pathways warranting continued investigation.

3 · Anti-Inflammatory Mechanisms

Chronic low-grade inflammation is now recognised as a shared root mechanism in type 2 diabetes, cardiovascular disease, metabolic syndrome, and neurodegenerative conditions. Cinnamon's anti-inflammatory profile operates at multiple molecular levels. Cinnamaldehyde modulates NF-κB — the master regulator of inflammatory gene expression — reducing downstream cytokine production including TNF-α, IL-1β, and IL-6 in preclinical models.[2] Separately, eugenol — present in Ceylon cinnamon but essentially absent from cassia — has demonstrated COX-2 inhibitory activity in vitro.[5] These represent two mechanistically distinct anti-inflammatory pathways present in Ceylon's phytochemical composition that are not both present in cassia. Human clinical evidence for meaningful in vivo anti-inflammatory effects remains an area requiring larger, well-designed trials.

4 · Antioxidant Chemistry

Ceylon cinnamon bark extracts consistently demonstrate free radical scavenging activity in validated in vitro assays, with the polyphenolic and flavonoid fractions identified as primary contributors.[6] These compounds interact with reactive oxygen species — superoxide, hydroxyl, and peroxyl radicals — across multiple chemical classes simultaneously. In vitro antioxidant activity does not automatically predict equivalent in vivo effects, where bioavailability, metabolism, and tissue distribution introduce complexity. What the analytical literature establishes clearly is the chemical richness of Ceylon cinnamon's polyphenolic matrix — a well-characterised substrate for ongoing mechanistic and clinical research.

5 · Neuroprotection & Cognitive Function

A systematic review (PMID 36652384)[13] examined over 40 studies addressing cinnamon and cognitive function. Of those, only two were human clinical trials — one positive, one showing no significant change. The vast majority of the evidence base is preclinical, from animal models and cell culture systems. Within that literature, several mechanistically specific findings have attracted attention: inhibition of tau protein aggregation, reduction of beta-amyloid plaque formation in animal models of Alzheimer's disease, and early investigation of CEppt — a water-soluble cinnamon bark compound — in transgenic Alzheimer's mouse models. Human clinical conclusions cannot yet be drawn in this domain. This is a scientifically promising direction requiring substantially more rigorous human trial data before cognitive health claims can be substantiated.

6 · Antimicrobial Activity

Cinnamaldehyde and eugenol demonstrate bactericidal and bacteriostatic activity against a broad spectrum of clinically relevant organisms — including Staphylococcus aureus, Escherichia coli, Salmonella species, Helicobacter pylori, and multiple Candida species — across multiple independent laboratory studies.[5] Activity against MRSA has been reported in laboratory models, though translating in vitro antimicrobial activity into clinical applications requires substantially more development. In oral health, cinnamon extracts have demonstrated inhibitory effects on Streptococcus mutans (primary driver of dental caries) and Porphyromonas gingivalis (a key periodontal pathogen).

7 · Emerging Oncological Research

Oncological research involving cinnamon is genuinely preliminary — no clinical claims of cancer prevention or treatment are supported by the current evidence. What does exist is a body of preclinical research generating scientifically credible hypotheses. A 2023 preclinical study demonstrated that cinnamon extract induces apoptosis in blood cancer cell lines and inhibits growth factor-mediated tumour proliferation in animal models.[3] The molecular thread connecting these findings to other documented cinnamon activities is NF-κB inhibition — a pathway central to both inflammatory responses and cancer cell survival signalling. These findings represent a scientifically interesting early-stage research direction warranting further investigation, communicated with the precision and humility the evidence currently demands.

── PART THREE · THE CRITICAL DISTINCTION ──

The four commercial cinnamon species contain broadly similar aromatic and polyphenolic compounds. They do not share the same safety profile — specifically with respect to coumarin, a compound whose differential distribution between species is among the most important and least well-communicated facts in food and ingredient science.

Coumarin (1,2-benzopyrone, CAS 91-64-5) is a naturally occurring aromatic lactone found in tonka beans, sweet clover, and at high concentrations in cassia, Saigon, and Korintje cinnamon. In rodent studies, coumarin induces hepatotoxicity through the 3,4-coumarin epoxidation pathway.[7] Human metabolism is predominantly via 7-hydroxylation — a safer route in most individuals — but genetic polymorphism in CYP2A6 means individual metabolic capacity varies significantly, and some individuals may be more susceptible to adverse effects at lower cumulative doses.[14]

Coumarin Content by Cinnamon Species — Analytical Data & Safety Assessment

── PART FOUR · WHY CINNAMOMUM VERUM ──

The modern evidence does not support treating "cinnamon" as a uniform ingredient category. Species identity, coumarin burden, extract composition, and traceability materially affect both the interpretation of the scientific literature and the suitability of any cinnamon ingredient for repeated-use applications. The preceding sections have established the phytochemical depth of cinnamon as a genus and the critical safety variable that separates its commercial species. This section examines the seven dimensions on which Cinnamomum verum — Ceylon cinnamon — is most clearly distinguished from its commercial relatives. The case rests not on origin sentiment or historical prestige alone, but on documented chemistry, authenticated clinical evidence, a well-characterised safety profile, and a legal provenance framework that no other commercial cinnamon species currently possesses.

Cassia's essential oil is approximately 95% cinnamaldehyde — a single-compound profile. Ceylon cinnamon's oil contains cinnamaldehyde (50–63%) alongside eugenol, cinnamyl acetate, linalool, alpha-terpineol, terpinolene, and benzyl benzoate.[2] Eugenol alone adds documented COX-2 inhibitory and antimicrobial activities that are structurally absent from cassia's composition. The scientific concept of phytochemical synergy — that naturally co-occurring compounds in botanical extracts produce activities exceeding what isolated constituents would predict — makes this complexity biologically meaningful, not merely analytical.

Ceylon cinnamon bark is characterised by high PAC-A concentrations — the polymeric flavonoid fraction identified as the primary mediator of cinnamon's insulin-mimetic activity in preclinical research. Standardised Ceylon extracts have been characterised at up to 15,298 mg PAC-A per 100g (BL-DMAC method).[4] The 2025 PLoS ONE RCT used ≥30% PAC-A standardisation as its formulation specification — derived from prior dose-response research on C. zeylanicum. PAC-A characterisation and standardisation have been most extensively developed in C. zeylanicum extracts — the research infrastructure built around this species' polyphenolic profile is the most advanced among commercial cinnamon varieties.

Ceylon cinnamon typically contains 4–20 mg coumarin per kilogram of bark — levels that in authenticated Sri Lankan samples frequently fall below analytical detection thresholds.[15] Cassia consistently tests at 2,650–7,017 mg/kg — approximately two to three orders of magnitude higher. Against EFSA's TDI of 0.1 mg/kg/day, routine cassia consumption at culinary doses approaches or exceeds the safe threshold.[7] A 2012 review in Diabetic Medicine examining 16 Ceylon cinnamon studies in diabetic subjects found beneficial metabolic effects with no detected hepatotoxic signals — a safety profile that is more difficult to establish with higher-coumarin cinnamon species at comparable intake levels.

The most methodologically rigorous clinical trials have converged on authenticated C. zeylanicum as their study material — reflecting the growing awareness of inter-species compositional differences and the practical advantage of extract standardisation: Ceylon cinnamon extracts can be standardised to defined PAC-A polyphenol content, enabling reproducible dosing and study-to-study comparability that cassia extracts have not achieved. The 2025 PLoS ONE RCT,[4] the 2017 Phase I safety trial (Ranasinghe et al.),[12] and the 2025 systematic review (Beheshti et al.)[9] all explicitly document species authentication, extract characterisation, and coumarin quantification. For regulatory submissions and science-backed formulation claims, the species specificity of the evidence base is not an academic footnote — it is the difference between data that supports your product and data that is unrelated to it.

On 2 February 2022, following a decade-long process involving the Sri Lanka Export Development Board, UNIDO, the WTO, the EU Delegation to Sri Lanka, and the International Trade Centre — overcoming formal objections from competing exporting nations — the EU Commission formally entered "Ceylon Cinnamon" into its register of Protected Geographical Indications under Implementing Regulation (EU) 2022/144.[16] This is a legal instrument, not a quality award: only cinnamon grown, processed, and manufactured in Sri Lanka can be marketed under the name "Ceylon Cinnamon" in EU markets. UNIDO established a blockchain-based traceability system across the entire value chain as part of this process.[17] In January 2024, the IFC confirmed GI certification for 45 Ceylon cinnamon producers, extending traceability to farm level.[18] At the national level, Sri Lanka's Department of Cinnamon Development administers its own GI certification programme covering cut cinnamon, cinnamon powder, cinnamon leaf oil, and cinnamon bark oil — providing a parallel domestic protection framework that complements the EU PGI.[20]

The sensory distinction between Ceylon and cassia cinnamon is a direct expression of their chemical difference. Cassia's 95% cinnamaldehyde dominance produces an intense, single-note flavour. Ceylon's multi-compound essential oil profile — cinnamaldehyde balanced by cinnamyl acetate, eugenol, linalool, and multiple minor terpenes[2] — produces a flavour commonly described as complex, sweet, and floral, with a delicacy that cassia's simpler composition are difficult to replicate. The chemical basis for this distinction is analytically measurable; the sensory consequence follows directly from the chemistry.

Cinnamomum verum is indigenous to Sri Lanka. Cinnamon cultivation on the island is documented as far back as 1400 BCE,[20] and the first written reference specifically to Ceylon cinnamon appears in the tenth-century Arabic text Aja'ib al-Hind by Burzug ibn Shahriyar. Portuguese historian Diogo do Couto recorded that during the reign of King Parakramabahu (1236–1270 AD), the island was already renowned for the fine quality and abundance of its cinnamon — evidence that Ceylon's reputation for superior quality predates European contact by centuries.[20]

Encyclopaedia Britannica records that cinnamon was once more valuable than gold and was later the most profitable spice in the Dutch East India Company trade.[1] The colonial control sequence is itself a record of Ceylon cinnamon's singular value: the Portuguese established control from 1505; the Dutch VOC took over in 1658 and initiated the first systematic commercial cultivation between 1765 and 1785 under Governor Iman Willem Falck; by 1799 British Governor Frederick North had secured prime cinnamon lands in Colombo and Negombo; and by 1850 approximately 40,000 acres of plantation had been established across the island.[20] The British succeeded the Dutch in 1796. For nearly five consecutive centuries, three of the most powerful commercial and military empires in history competed specifically to control this island's cinnamon. Few botanicals in recorded history have such a well-documented record of sustained trade importance and geopolitical competition.[20][1] The Department of Cinnamon Development's own 2024 Performance Report notes that from the 16th century onward, for nearly five centuries, Ceylon cinnamon was a primary reason for Sri Lanka being partially and fully colonised by Western powers.

The environmental conditions of Sri Lanka's southwestern coastal belt define what true Ceylon cinnamon is — they are not merely agricultural context but part of its scientific identity. Official Sri Lankan government records document the specific growing requirements: annual temperatures of 25–35°C, rainfall exceeding 1,875mm per year, relative humidity of 75–85%, elevation up to 700 metres above sea level, and the red-yellow podzolic soils of Sri Lanka's wet zone.[20] These conditions shape the phytochemical composition of the bark — the reason why authenticated C. zeylanicum extracts from Sri Lanka are associated with the PAC-A polyphenol concentrations documented in the clinical literature. Production remains artisanal in a quality-determining sense: skilled peelers — known as chalias — hand-peel feather-thin inner bark layers that curl naturally as they dry into the characteristic multi-layered pale tan quills that are the visual and physical hallmark of true cinnamon. This tradition of artisanal processing is unique to Sri Lanka and represents accumulated knowledge developed over centuries. The EU PGI granted in 2022 and Sri Lanka's own national GI certification programme are the contemporary legal expression of a recognition that is, in documented historical terms, more than three thousand years old.

── PART FIVE · SCIENTIFIC APPLICATIONS ──

The biological activities documented for Cinnamomum verum translate into distinct formulation applications, each with its own evidence requirements and regulatory context. The following survey outlines the primary domains where authenticated Ceylon cinnamon is scientifically most relevant.

── CONCLUSION ──

Cinnamon has well-documented historical significance in trade and medicine across multiple civilisations — from Egyptian ritual contexts (~2000 BCE) through Ayurvedic medical texts, classical Greek and Roman pharmacology, and into the most economically competitive era of the global spice trade. Historical records consistently show that cinnamon held exceptional commercial and medicinal value across independent cultures. That record is the context for modern scientific investigation, not a substitute for it.

Modern science supports several plausible and — in specific areas — clinically relevant biological activities associated with cinnamon. Mechanistic and preclinical data describe coherent pathways for anti-inflammatory, antioxidant, antimicrobial, and metabolic effects. Human clinical evidence is most developed for blood glucose modulation, where the best-controlled recent trial — using authenticated Cinnamomum zeylanicum extract standardised to ≥30% PAC-A polyphenols — showed a statistically significant effect on fasting blood glucose. Broader clinical applications remain areas of ongoing and promising investigation rather than established outcomes, and the U.S. National Center for Complementary and Integrative Health notes that current evidence does not yet support definitive clinical use for any specific health condition.[19]

The evidence base is not uniform across cinnamon species — a point the scientific literature now emphasises clearly. Differences in coumarin burden, essential oil composition, PAC-A polyphenol content, and available clinical data mean that conclusions drawn from studies of one species cannot be applied to another. Among the commercial species, Cinnamomum verum is the most consistently characterised: it presents the lowest coumarin burden (confirmed negligible or undetectable in verified Sri Lankan samples by EFSA-cited analytical data[7]), the most developed extract standardisation framework, the strongest species-authenticated clinical research base, and the only EU Protected Geographical Indication among commercial cinnamon varieties.

For formulators, ingredient buyers, and informed consumers: among the commercial cinnamon species, authenticated Cinnamomum verum offers the best convergence of species-specific clinical evidence, safety specification, and documented provenance for repeated-use applications. It is the species where the safety data, the phytochemical data, the clinical data, and the regulatory recognition are all most coherently aligned. That is not a marketing claim — it is the current state of the science.

Sources: EFSA Scientific Opinion on Coumarin (2004) · BfR Health Assessment No. 043/2006 · Blahová & Svobodová (2012), PMC3385612